- Home
- SYF vs ROIV Comparison
SYF vs ROIV Comparison
Compare SYF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYF | ROIV |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United Kingdom |
| Employees | 20000 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SYF | ROIV |
|---|---|---|
| Price | $65.35 | $28.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $86.42 | $27.56 |
| AVG Volume (30 Days) | 3.5M | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $84.34 | N/A |
| Revenue Next Year | $4.94 | $385.85 |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.55 | $8.73 |
| 52 Week High | $88.77 | $30.33 |
Technical Indicators
Market Signals| Indicator | SYF | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 54.73 |
| Support Level | N/A | $26.94 |
| Resistance Level | $75.52 | N/A |
| Average True Range (ATR) | 2.04 | 0.97 |
| MACD | -0.21 | -0.29 |
| Stochastic Oscillator | 18.41 | 39.05 |
Price Performance
Historical ComparisonAbout SYF Synchrony Financial
Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.